ENDRA Life Sciences Management
Management criteria checks 2/4
ENDRA Life Sciences' CEO is Alex Tokman, appointed in Aug 2024, has a tenure of 1.33 years. total yearly compensation is $398.98K, comprised of 28.6% salary and 71.4% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth $23.87. The average tenure of the management team and the board of directors is 1.3 years and 8 years respectively.
Key information
Alex Tokman
Chief executive officer
US$399.0k
Total compensation
| CEO salary percentage | 28.63% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.0004% |
| Management average tenure | 1.3yrs |
| Board average tenure | 8yrs |
Recent management updates
Recent updates
ENDRA to submit FDA De Novo request for liver disease monitoring system in coming weeks
Sep 29ENDRA Life Sciences receives European patent for TAEUS system
Aug 24Endra Life Sciences Q2 2022 Earnings Preview
Aug 12We're A Little Worried About ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate
Aug 08
We're Keeping An Eye On ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate
Nov 18We Think ENDRA Life Sciences (NASDAQ:NDRA) Needs To Drive Business Growth Carefully
Jul 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$8m |
| Jun 30 2025 | n/a | n/a | -US$9m |
| Mar 31 2025 | n/a | n/a | -US$10m |
| Dec 31 2024 | US$399k | US$114k | -US$12m |
| Sep 30 2024 | n/a | n/a | -US$9m |
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$10m |
| Dec 31 2023 | US$103k | n/a | -US$10m |
| Sep 30 2023 | n/a | n/a | -US$12m |
| Jun 30 2023 | n/a | n/a | -US$12m |
| Mar 31 2023 | n/a | n/a | -US$13m |
| Dec 31 2022 | US$81k | n/a | -US$13m |
| Sep 30 2022 | n/a | n/a | -US$13m |
| Jun 30 2022 | n/a | n/a | -US$12m |
| Mar 31 2022 | n/a | n/a | -US$12m |
| Dec 31 2021 | US$106k | n/a | -US$11m |
| Sep 30 2021 | n/a | n/a | -US$10m |
| Jun 30 2021 | n/a | n/a | -US$11m |
| Mar 31 2021 | n/a | n/a | -US$11m |
| Dec 31 2020 | US$101k | n/a | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$19m |
| Jun 30 2020 | n/a | n/a | -US$19m |
| Mar 31 2020 | n/a | n/a | -US$18m |
| Dec 31 2019 | US$259k | n/a | -US$18m |
Compensation vs Market: Alex's total compensation ($USD398.98K) is below average for companies of similar size in the US market ($USD596.08K).
Compensation vs Earnings: Alex's compensation has increased whilst the company is unprofitable.
CEO
Alex Tokman (63 yo)
Mr. Alexander Y. Tokman, also known as Alex, served as an Acting CEO and Director at ENDRA Life Sciences Inc. from August 13, 2024 to 2025 and also serves as its Chief Executive Officer since 2025 and also...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 1.3yrs | US$398.98k | 0.00043% $ 23.9 | |
| CFO & Secretary | 1.3yrs | US$241.48k | no data | |
| Co-Founder | no data | no data | no data | |
| Head of Operations | less than a year | no data | no data | |
| Head of Regulatory & Clinical Affairs | 1.3yrs | no data | no data | |
| Head of Engineering | less than a year | no data | no data |
Experienced Management: NDRA's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 17.9yrs | US$398.98k | 0.00043% $ 23.9 | |
| Independent Director | 12.9yrs | US$40.95k | 6.08% $ 337.4k | |
| Independent Director | 10.4yrs | US$40.95k | 0.00017% $ 9.4 | |
| Independent Director | 5.7yrs | US$40.95k | 0.000090% $ 5.0 | |
| Member of Cryptocurrency Advisory Board | less than a year | no data | no data | |
| Scientific Advisor | 10.3yrs | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Member of Cryptocurrency Advisory Board | less than a year | no data | no data | |
| Member of Cryptocurrency Advisory Board | less than a year | no data | no data |
Experienced Board: NDRA's board of directors are considered experienced (8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/31 14:21 |
| End of Day Share Price | 2025/12/31 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ENDRA Life Sciences Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Kyle Bauser | Colliers Securities |